Data from Roivant Sciences Ltd.’s Phase IIb TUSCANY-2 trial of RVT-3101 set the anti-TL1A antibody up as a potential blockbuster treatment for ulcerative colitis amid what looks to become stiff competition with competitor PRA023 from Prometheus Biosciences, Inc, which Merck & Co., Inc. recently acquired.
Following previously disclosed induction phase data from TUSCANY-2, Roivant announced results on 22 June for all-comers as well as those...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)